Cutaneous lupus erythematosus

Related records

Broader conditions (8)

• Autoimmune disease
• Connective tissue disorder
• Disease
• Disease by body system or component
• Human disease
• Immune system disorder
• Lupus erythematosus
• Rheumatic disorder

Narrower conditions (12)

• Bullous systemic lupus erythematosus
• Chilblain lupus
• Chilblain lupus 1
• Chilblain lupus 2
• Chronic cutaneous lupus erythematosus
• Discoid lupus erythematosus
• Familial chilblain lupus
• Hypertrophic or verrucous lupus erythematosus
• Lupus erythematosus panniculitis
• Lupus erythematosus tumidus
• Rowell syndrome
• Subacute cutaneous lupus erythematosus

Trials (63)

• A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
• A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
• A Non-drug Study Profiling Cutaneous Lupus
• A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
• A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
• A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
• A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus
• A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
• A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
• A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
• A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
• A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
• A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
• A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
• A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
• A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

Drugs in development (25)

• Afimetoran Phase 1
• Alitretinoin Phase 2
• AMG-557 Phase 1
• Anifrolumab Phase 3
• Dazukibart Phase 2
• Deucravacitinib Phase 2
• Dovramilast Phase 2
• Eclitasertib Phase 2
• Edecesertib Phase 2
• Enpatoran Phase 1
• Ergocalciferol Phase 2
• Etanercept Phase 2
• Filgotinib Phase 2
• Fumaric acid Phase 2
• Human immunoglobulin G Early phase 1
• Hydroxychloroquine Phase 3
• Hydroxychloroquine sulfate Phase 3
• Lanraplenib Phase 2
• Litifilimab Phase 3
• Mocravimod Phase 2

Other linked drugs (2)

• Imiquimod
• Tapinarof